

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	Serial No:	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	28 July 2000	Art Unit:	1643

### U.S. PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
	<b>D324</b>	4,816,397	28 Mar 1989	Boss			
	<b>D325</b>	4,816,567	28 Mar 1989	Cabilly			
	<b>D326</b>	5,225,535	6 Jul 1993	Winter			
	<b>D327</b>	5,250,732	5 Oct 1993	Kogan			
	<b>D328</b>	5,530,101	25 Jun 1996	Queen			
	<b>D329</b>	5,691,135	25 Nov 1997	Braun			
	<b>D330</b>	6,399,649 B1	7 Aug 2003	Anderson			
	<b>D331</b>	7,381,560 B2	3 Jun 2008	Anderson			
	<b>D332</b>	7,422,739 B2	9 Sep 2008	Anderson			
	<b>D333</b>	2008/0038261 A1	14 Feb 2008	Grillo-López			

### FOREIGN PATENT DOCUMENTS

INITIAL	INDEX	DOCUMENT	DATE	COUNTRY	CLASS	SUB.	TRANSLATION	
							YES	NO
	<b>D334</b>	0 274 394 A2	13 Jul 1988	EP				
	<b>D335</b>	94/ 08601	28 Apr 1994	WO				
	<b>D336</b>	98/ 42378	1 Oct 1998	WO				

**EXAMINER**  
/Alana M. Harris/

**DATE**  
**CONSIDERED 11 February 2009**

Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**Form PTO-1449 (modified)**

**SHEET 1 OF 4**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	<b>Serial No:</b>	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	28 July 2000	Art Unit:	1643

### OTHER DOCUMENTS

INITIAL	INDEX	CITATION
	<b>D337</b>	Alas S. <i>et al.</i> <i>Anticancer Res.</i> 20(5A): 2961-66, 2000. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
	<b>D338</b>	Arranz R. <i>et al.</i> <i>J. Clin. Oncol.</i> 16(4): 1538-46, 1998. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
	<b>D339</b>	Belhadj K. <i>et al.</i> <i>Ann. Oncol.</i> 15: 504-10, 2004. Efficiency of <i>in vivo</i> purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
	<b>D340</b>	Berinstein N. <i>et al.</i> <i>Proc. Amer. Assn. Cancer Res.</i> 38: 85, abst. no. 567, March 1997. IDEC-C2B8 (rituximab) levels correlate with response in low-grade or follicular non-Hodgkin's lymphoma (LG-F-NHL).
	<b>D341</b>	Bierman P.J. <i>et al.</i> (in) Hoffman, R., ed., <i>Hematology</i> , 2d. ed. (Churchill Livingstone), 1995. Chapter 81, pages 1278-98. Clinical manifestations and staging of and therapy for non-Hodgkin's lymphomas.
	<b>D342</b>	Byrd J.C. <i>Cancer Biother. Radiopharm.</i> 14(4)L 323, 1999. Rituximab therapy in patients with chronic lymphocytic leukemia.
	<b>D343</b>	Cheson B.D. <i>et al.</i> <i>Blood</i> 87: 4990-97, 1996. National Cancer Institute-specified working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.
	<b>D344</b>	Chow K.U. <i>et al.</i> <i>Haematologica</i> 87: 33-43, 2002. Anti-CD20 antibody (IDE-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes <i>in vitro</i> : role of cytokines, complement, and caspases.
	<b>D345</b>	Eisenbeis C.F. <i>et al.</i> <i>Clin. Cancer Res.</i> 10: 6101-10 (2004). Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
	<b>D346</b>	Engert A. <i>et al.</i> <i>Ann. Hematol.</i> 77(suppl. 2): S180, abst. no. 717. Multicenter phase II study of the monoclonal anti-CD20 antibody rituximab (IDE-C2B8) in patients with intermediate/high grade non-Hodgkin's lymphoma.
	<b>D347</b>	Foran J.M. <i>et al.</i> <i>Br. J. Haematol.</i> 102(1): 149, 1998. Immunotherapy of mantle cell lymphoma (MCL), lymphoplasmacytoid lymphoma (LPC) and Waldenstrom's macroglobulinemia (WM), and small lymphocytic leukemia (SLL) with rituximab (IDE-C2B8): preliminary results of an ongoing international multicentre trial.

<b>EXAMINER</b> <i>/Alana M. Harris/</i>	<b>DATE</b> <b>CONSIDERED 11 February 2009</b>
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 2 OF 4</b>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	<b>Serial No:</b>	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	28 July 2000	Art Unit:	1643

D348	Fridik M.A. et al. <i>Ann. Hematol.</i> 74(1): 7-10, 1997. First-line treatment of Waldenström's disease with cladribine.
D349	Gianni A.M. et al. <i>Blood</i> 102: 749-55, 2003. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
D350	Ginaldi L. et al. <i>J. Clin. Pathol.</i> 51: 364-69, 1998. Levels of expression of CD19 and CD20 in chronic B leukaemias.
D351	Golay J. et al. <i>Haematologica</i> 88: 1002-12, 2003. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
D352	Gribben J.G. et al. <i>N. Engl. J. Med.</i> 325(22): 1525-32, 1991. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
D353	Hillmen P. et al. <i>Semin. Oncol.</i> 31(1 suppl. 2): 22-26, 2004. Advancing therapy for chronic lymphocytic leukemia – the role of rituximab.
D354	IDEC Pharmaceuticals Corp., press release dated 9 December 1996. IDEC Pharmaceuticals and Genentech announce positive final results for pivotal phase III trial of IDEC-C2B8 as single agent.
D355	Imrie, K. et al. <i>Curr. Oncol.</i> 6(4): 228-35, 1999. Use of rituximab in the treatment of lymphoma: an evidence summary.
D356	Jazirehi A.R. et al. <i>Oncogene</i> 24: 2121-43, 2005. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
D357	Keating M. et al. <i>Semin. Oncol.</i> 27(6 suppl. 12): 86-90, 2000. High-dose rituximab therapy in chronic lymphocytic leukemia.
D358	Maddy A.H. et al. <i>Immunol.</i> 68(3): 346-52, 1989. The role of cell maturation in the generation of phenotypic heterogeneity in B-cell chronic lymphocytic leukaemia.
D359	Marti G.E. et al. <i>Ann. N.Y. Acad. Sci.</i> 651: 480-83, 1992. CD20 and CD5 expression in B-chronic lymphocytic leukemia.
D360	Mazza P. et al. <i>Bone Marrow Trans.</i> 23: 1273-78, 1999. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report.
D361	Nguyen D.T. et al. <i>Eur. J. Haematol.</i> 62: 76-82, 1999. IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.

<b>EXAMINER</b> /Alana M. Harris/	<b>DATE</b> <b>CONSIDERED</b> 11 February 2009
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 3 OF 4</b>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01201	<b>Serial No:</b>	<b>09/ 436,347</b>
	Inventor(s):	Christine WHITE <i>et al.</i>	Examiner:	A.M. HARRIS
	Filed:	28 July 2000	Art Unit:	1643

<b>D362</b>	O'Brien S.M. et al. <i>J. Clin. Oncol.</i> 19: 2165-70, 2001. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
<b>D363</b>	Piro L. et al. <i>Blood</i> 90(10 Suppl. 1): 510a, abst. no. 2272, 1997. RITUXAN™ (rituximab, IDEC-C2B8): Interim analysis of a phase II study of once weekly times 8 dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma.
<b>D364</b>	Rai K.R. et al. (in) R. Hoffman, R., ed., <i>Hematology</i> , 2d. ed. (Churchill Livingstone), 1995. Chapter 83, pages 1308-19. Chronic lymphocytic leukemia.
<b>D365</b>	Saville, M.W. Statement of M. Wayne Saville, M.D., dated 20 December 2007, submitted by applicant in Taiwan (R.O.C.) patent application no. 088119557.
<b>D366</b>	van der Kolk, L.E. et al. <i>Blood</i> 92(10 Suppl. 1): 512a-513a, abst. no. 2284, 1997. Phase I/II clinical trial to evaluate the safety and efficacy of a chimeric anti-CD20 monoclonal antibody (rituximab) and G-CSF given weekly to patients with relapsed B-cell lymphoma.
<b>D367</b>	Witzig T.E. et al. <i>Am. J. Clin. Pathol.</i> 101: 312-17, 1994. Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia.
<b>D368</b>	Zhou X. et al. <i>Chinese Pharm. J.</i> 30(8): 453-54, 1995. 细胞因子疗法在肿瘤治疗中的应用. (English translation of abstract provided.)

<b>EXAMINER</b> <i>/Alana M. Harris/</i>	<b>DATE</b> <b>CONSIDERED</b> 11 February 2009
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	
<b>Form PTO-1449 (modified)</b>	<b>SHEET 4 OF 4</b>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AH/